Adenovirus vectors for gene therapy, vaccination and cancer gene therapy

Wold, William; Toth, Karoly

doi:10.2174/1566523213666131125095046

Cited by 555Virus-based gene therapy researchImmunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy

Open access

Wold, William, Toth, Karoly·2014·Current Gene Therapy

DOI 10.2174/1566523213666131125095046PMC PMC4507798

Open this paper in CoChat — free account

Abstract

Adenovirus vectors are the most commonly employed vector for cancer gene therapy. They are also used for gene therapy and as vaccines to express foreign antigens. Adenovirus vectors can be replication-defective; certain essential viral genes are deleted and replaced by a cassette that expresses a foreign therapeutic gene. Such vectors are used for gene therapy, as vaccines, and for cancer therapy. Replication-competent (oncolytic) vectors are employed for cancer gene therapy. Oncolytic vectors are engineered to replicate preferentially in cancer cells and to destroy cancer cells through the natural process of lytic virus replication. Many clinical trials indicate that replication-defective and replication-competent adenovirus vectors are safe and have therapeutic activity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2174/1566523213666131125095046

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Transduction of adenoviral vectors activates innate immune signaling pathways and stimulates immune cells to secrete pro-inflammatory cytokines for robust adaptive immune response, making them useful for a vaccine vehicle.
“As the transduction of the Ad activates innate immune signaling pathways and stimulates immune cells to secrete pro-inflammatory cytokines for robust adaptive immune response, these properties make the adenoviral vector useful for a vaccine vehicle [56].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [56]
Adenoviral vector vaccines have been extensively studied for safety, and adenoviral vector-based therapeutic drugs are used in clinical practice.
“The safety of adenoviral vector vaccines has been extensively studied, and adenoviral vector-based therapeutic drugs are used in clinical practice.5, 6, 7”
From Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia (2021) · cites this paper as [6]
The development of gutless adenoviral vectors allows us to circumvent antiadenoviral vector immunity.
“Second, the development of gutless adenoviral vectors allows us to circumvent antiadenoviral vector immunity.”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [63]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713 · see citing works
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer
Raper, S. E., Chirmule, N. B., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,502 · see citing works
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Khuri, F. R., Nemunaitis, J. J., Ganly, I., Arseneau, J. C., Tannock, I. F., Romel, L., Gore, M. E., Ironside, J. A. D., MacDougall, R. H., Heise, C. C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,099 · see citing works
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
Heise, C. C., Sampson-Johannes, A., Williams, A., McCormick, F. P., Hoff, D. D. V., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 941 · see citing works
The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response
Muruve, D. A., Pétrilli, V., Zaiss, A. K., White, L. R., Clark, S. A., Ross, P. J., Parks, R. J., & Tschopp, J. (2008) · Nature · doi:10.1038/nature06664 · Cited by 936 · see citing works
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo-Margareto, J., Gomez‐Manzano, C., Alemany, R., Lee, P. S. Y., McDonnell, T. J., Mitlianga, P. G., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764 · see citing works
A Helper-Dependent Adenovirus Vector System: Removal of Helper Virus by Cre-Mediated Excision of the Viral Packaging Signal
Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725 · see citing works
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S., Keefer, M. C., Tomaras, G. D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310566 · Cited by 597 · see citing works
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise, C. C., Hermiston, T. W., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L. K., & Kirn, D. H. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 584 · see citing works
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Hecht, J. R., Bedford, R. A., Abbruzzese, J. L., et al. (2003) · PubMed · Cited by 493 · see citing works
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006) · Nature · doi:10.1038/nature04721 · Cited by 490 · see citing works
Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Peng, Z. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1016 · Cited by 437 · see citing works
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14
Wang, H., Li, Z.-Y., Liu, Y., Persson, J., Beyer, I., Möller, T., Koyuncu, D., Drescher, M. R., Strauss, R., Zhang, X., et al. (2010) · Nature Medicine · doi:10.1038/nm.2270 · Cited by 436 · see citing works
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Ganly, I., Kirn, D. H., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C. C., et al. (2000) · PubMed · Cited by 432 · see citing works
The Innate Immune Response to Adenovirus Vectors
Muruve, D. A. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1157 · Cited by 408 · see citing works
Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism
Krasnykh, V. N., Mikheeva, G., Douglas, J. T., & Curiel, D. T. (1996) · Journal of Virology · doi:10.1128/jvi.70.10.6839-6846.1996 · Cited by 387 · see citing works
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.
DeWeese, T. L., der Poel, H. V., Li, S., et al. (2001) · PubMed · Cited by 384 · see citing works
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
O’Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C. R., Shen, A., Boyle, L., Pandey, K., Soria, C. T., Kunich, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.11.012 · Cited by 370 · see citing works
Innate Immune Response to Adenoviral Vectors Is Mediated by both Toll-Like Receptor-Dependent and -Independent Pathways
Zhu, J., Huang, X., & Yang, Y. (2007) · Journal of Virology · doi:10.1128/jvi.02192-06 · Cited by 370 · see citing works
Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein
Sumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., PETER, T. F., Peyerl, F. W., Kishko, M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7179 · Cited by 369 · see citing works
Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
Freytag, S. O., Khil, M. S., Stricker, H. J., et al. (2002) · PubMed · Cited by 310 · see citing works
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
Reid, T. R., Galanis, E., Abbruzzese, J. L., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C. C., Uprichard, M. J., Hatfield, M. J., et al. (2002) · PubMed · Cited by 309 · see citing works
Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial
Mulvihill, S. J., Warren, R. S., Venook, A. P., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301398 · Cited by 299 · see citing works
Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency
Wilson, J. M. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.12.016 · Cited by 299 · see citing works
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity
Nemunaitis, J. J., Cunningham, C. C., Buchanan, A., Blackburn, A., Edelman, G. M., Maples, P. B., Netto, G. J., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283 · see citing works
Clinical Trials with Oncolytic Adenovirus in China
Yu, W., & Fang, H. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780058817 · Cited by 274 · see citing works
Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.
Freytag, S. O., Stricker, H. J., Pegg, J., et al. (2003) · PubMed · Cited by 264 · see citing works
New Insights on Adenovirus as Vaccine Vectors
Lasaro, M. O., & Ertl, H. C. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.130 · Cited by 263 · see citing works
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
Reid, T., Warren, R. S., & Kirn, D. H. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700539 · Cited by 258 · see citing works
Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer
Vasey, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1562 · Cited by 246 · see citing works
Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art
Hostetler, K. Y. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.01.005 · Cited by 244 · see citing works
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial
Reid, T. R., Galanis, E., Abbruzzese, J. L., Sze, D. Y., Andrews, J. C., Romel, L., Hatfield, M. J., Rubin, J., & Kirn, D. H. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301512 · Cited by 243 · see citing works
Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
Koski, A., Kangasniemi, L., Escutenaire, S., Pesonen, S. A., Cerullo, V., Diaconu, I., Nokisalmi, P., Raki, M., Rajecki, M., Guse, K., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.161 · Cited by 243 · see citing works
[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].
Xia, Z.-J., Chang, J.-H., Zhang, L., et al. (2004) · PubMed · Cited by 241 · see citing works
A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen–Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer
Small, E. J., Carducci, M. A., Burke, J. M., Rodriguez, R., Fong, L. H., Ummersen, L. V., Yu, D., Aimi, J., Ando, D. G., Working, P. K., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.011 · Cited by 241 · see citing works
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial
Westphal, M., Ylä‐Herttuala, S., Martin, J. F., Warnke, P. C., Meneï, P., Eckland, D. J. A., Kinley, J., Kay, R., & Ram, Z. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70274-2 · Cited by 239 · see citing works
How I treat adenovirus in hematopoietic stem cell transplant recipients
Lindemans, C. A., Leen, A. M., & Boelens, J. J. (2010) · Blood · doi:10.1182/blood-2010-04-259291 · Cited by 231 · see citing works
Epigenetic Reprogramming by Adenovirus e1a
Ferrari, R., Pellegrini, M. A., Horwitz, G. A., Xie, W., Berk, A. J., & Kurdistani, S. K. (2008) · Science · doi:10.1126/science.1155546 · Cited by 230 · see citing works
Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
Cerullo, V., Pesonen, S. A., Diaconu, I., Escutenaire, S., Arstila, P. T., Ugolini, M., Nokisalmi, P., Raki, M., Laasonen, L., Särkioja, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3567 · Cited by 226 · see citing works
A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity
Smaill, F., Jeyanathan, M., Smieja, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006843 · Cited by 204 · see citing works
Current Issues and Future Directions of Oncolytic Adenoviruses
Yamamoto, M., & Curiel, D. T. (2009) · Molecular Therapy · doi:10.1038/mt.2009.266 · Cited by 197 · see citing works
Adenovirus Membrane Penetration Activates the NLRP3 Inflammasome
Barlan, A., Griffin, T., McGuire, K. A., & Wiethoff, C. M. (2010) · Journal of Virology · doi:10.1128/jvi.01265-10 · Cited by 181 · see citing works
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Kanerva, A., Nokisalmi, P., Diaconu, I., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2546 · Cited by 178 · see citing works
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine
Gray, G., Buchbinder, S., & Duerr, A. C. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833d2d2b · Cited by 172 · see citing works
Coagulation Factor X Activates Innate Immunity to Human Species C Adenovirus
Doronin, K., Flatt, J. W., Paolo, N. C. D., Khare, R., Kalyuzhniy, O., Acchione, M., Sumida, J. P., Ohto, U., Shimizu, T., Akashi‐Takamura, S., et al. (2012) · Science · doi:10.1126/science.1226625 · Cited by 165 · see citing works
Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients
Liikanen, I., Ahtiainen, L., Hirvinen, M., Bramante, S., Cerullo, V., Nokisalmi, P., Hemminki, O., Diaconu, I., Pesonen, S. A., Koski, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.51 · Cited by 165 · see citing works
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
Cerullo, V., Diaconu, I., Kangasniemi, L., Rajecki, M., Escutenaire, S., Koski, A., Romano, V. C., Rouvinen, N., Tuuminen, T., Laasonen, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.113 · Cited by 159 · see citing works
A New Group B Adenovirus Receptor Is Expressed at High Levels on Human Stem and Tumor Cells
Tuve, S., Wang, H., Ware, C. B., Liu, Y., Gaggar, A., Bernt, K. M., Shayakhmetov, D. M., Li, Z., Strauss, R., Stone, D., et al. (2006) · Journal of Virology · doi:10.1128/jvi.01370-06 · Cited by 154 · see citing works
Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.
Makower, D., Rozenblit, A. M., Kaufman, H., et al. (2003) · PubMed · Cited by 149 · see citing works
Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy
Leen, A. M., Christin, A., Khalil, M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01689-07 · Cited by 141 · see citing works
Adenovirus p53 gene therapy
Roth, J. A. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.1.55 · Cited by 131 · see citing works
Safety of Local Delivery of Low- and Intermediate-Dose Adenovirus Gene Transfer Vectors to Individuals with a Spectrum of Morbid Conditions
Harvey, B., Maroni, J. M., O'Donoghue, K. A., Chu, K. W., Muscat, J. C., Pippo, A. L., Wright, C. E., Hollmann, C., Wisnivesky, J. P., Kessler, P., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340152712638 · Cited by 130 · see citing works
Oncolytic viral therapies
Lin, E. E., & Nemunaitis, J. J. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700733 · Cited by 129 · see citing works
Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma
Habib, N. A., Salama, H., Median, A. A. E. L. A., et al. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700431 · Cited by 127 · see citing works
Efficacy of Hospital Germicides against Adenovirus 8, a Common Cause of Epidemic Keratoconjunctivitis in Health Care Facilities
Rutala, W. A., Peacock, J. E., Gergen, M. F., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1419-1424.2006 · Cited by 126 · see citing works
Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: A pilot phase II clinical trial
Lü, W. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i24.3634 · Cited by 124 · see citing works
Oncolytic Adenoviruses for the Treatment of Human Cancer: Focus on Translational and Clinical Data
Pesonen, S. A., Kangasniemi, L., & Hemminki, A. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100219n · Cited by 120 · see citing works
A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients
Li, J., Liu, H., Xr, Z., Xu, J.-P., Hu, W.-K., Liang, M., Chen, S.-Y., Hu, F., & Chu, D.-T. (2008) · Gene Therapy · doi:10.1038/gt.2008.179 · Cited by 118 · see citing works
E1B-Deleted Adenovirus ( dl 1520) Gene Therapy for Patients with Primary and Secondary Liver Tumors
Habib, N. A., Sarraf, C., Mitry, R. R., et al. (2001) · Human Gene Therapy · doi:10.1089/10430340150218369 · Cited by 117 · see citing works
Prevalence, quantification and typing of adenoviruses detected in river and treated drinking water in South Africa
Heerden, J. V., Ehlers, M. M., Heim, A., et al. (2005) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2005.02617.x · Cited by 115 · see citing works
Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
Nokisalmi, P., Pesonen, S. A., Escutenaire, S., Särkioja, M., Raki, M., Cerullo, V., Laasonen, L., Alemany, R., Rojas, J. J., Cascalló, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3167 · Cited by 113 · see citing works
Clinical development directions in oncolytic viral therapy
Eager, R. M., & Nemunaitis, J. J. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.7 · Cited by 110 · see citing works
A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases
Kimball, K. J., Preuss, M. A., Barnes, M. N., Wang, M., Siegal, G. P., Wan, W., Kuo, H., Saddekni, S., Stockard, C. R., Grizzle, W. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0791 · Cited by 109 · see citing works
Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin
Reid, T. R., Freeman, S., Post, L. E., McCormick, F. P., & Sze, D. Y. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700819 · Cited by 102 · see citing works
Aerosol and Lobar Administration of a Recombinant Adenovirus to Individuals with Cystic Fibrosis. I. Methods, Safety, and Clinical Implications
Joseph, P. M., O'Sullivan, B. P., Lapey, A., Dorkin, H. L., Oren, J., Balfour, R., Perricone, M. A., Rosenberg, M., Wadsworth, S. C., Smith, A. E., et al. (2001) · Human Gene Therapy · doi:10.1089/104303401750298535 · Cited by 101 · see citing works
Integrin targeted oncolytic adenoviruses Ad5‐D24‐RGD and Ad5‐RGD‐D24‐GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors
Pesonen, S. A., Diaconu, I., Cerullo, V., Escutenaire, S., Raki, M., Kangasniemi, L., Nokisalmi, P., Dotti, G., Guse, K., Laasonen, L., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26216 · Cited by 99 · see citing works
Generation of a Kupffer Cell-evading Adenovirus for Systemic and Liver-directed Gene Transfer
Khare, R., May, S. M., Vetrini, F., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.71 · Cited by 95 · see citing works
Second-Generation Replication-Competent Oncolytic Adenovirus Armed with Improved Suicide Genes and ADP Gene Demonstrates Greater Efficacy without Increased Toxicity
Barton, K. N., Paielli, D. L., Zhang, Y., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.005 · Cited by 92 · see citing works
Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck
Nemunaitis, J. J., Clayman, G. L., Agarwala, S. S., Hrushesky, W. J. M., Wells, J. R., Moore, C. E., Hamm, J. T., Yoo, G. H., Baselga, J. M., Murphy, B. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1044 · Cited by 91 · see citing works
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
Nemunaitis, J. J., Cunningham, C., Tong, A. W., Post, L. E., Netto, G. J., Paulson, A. S., Rich, D., Blackburn, A., Sands, B. E., Gibson, B., et al. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700585 · Cited by 90 · see citing works
Avidity Binding of Human Adenovirus Serotypes 3 and 7 to the Membrane Cofactor CD46 Triggers Infection
Trinh, H. V., Lesage, G., Chennamparampil, V., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06181-11 · Cited by 90 · see citing works
A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers
Chang, J., Zhao, X., Wu, X., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7913 · Cited by 87 · see citing works
Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer
Hemminki, O., Diaconu, I., Cerullo, V., Pesonen, S. K., Kanerva, A., Joensuu, T. K., Kairemo, K., Laasonen, L., Partanen, K. P. L., Kangasniemi, L., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.115 · Cited by 87 · see citing works
Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001
Paolino, K., Sande, J. E., Perez‐Albuerne, E. D., et al. (2010) · Journal of Clinical Virology · doi:10.1016/j.jcv.2010.10.016 · Cited by 86 · see citing works
Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity.
Krasnykh, V. N., Dmitriev, I. P., Navarro, J. G., et al. (2000) · PubMed · Cited by 83 · see citing works
Helper-dependent adenoviral vectors for liver-directed gene therapy
Brunetti‐Pierri, N., & Ng, P. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr143 · Cited by 81 · see citing works
Analysis of Risk Factors for Local Delivery of Low- and Intermediate-Dose Adenovirus Gene Transfer Vectors to Individuals with a Spectrum of Comorbid Conditions
Crystal, R. G., Harvey, B., Wisnivesky, J. P., O'Donoghue, K. A., Chu, K. W., Maroni, J. M., Muscat, J. C., Pippo, A. L., Wright, C. E., Kaner, R. J., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340152712647 · Cited by 78 · see citing works
Oncolytic Adenoviruses for Cancer Immunotherapy
Cerullo, V., Koski, A., Vähä-Koskela, M. J. V., & Hemminki, A. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-398342-8.00008-2 · Cited by 76 · see citing works
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors
Pesonen, S. A., Nokisalmi, P., Escutenaire, S., Särkioja, M., Raki, M., Cerullo, V., Kangasniemi, L., Laasonen, L., Ribacka, C., Guse, K., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.17 · Cited by 72 · see citing works
Prostate Cancer Gene Therapy Clinical Trials
Freytag, S. O., Stricker, H. J., Movsas, B., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300162 · Cited by 71 · see citing works
Head and neck cancer: Response to p53‐based therapeutics
Nemunaitis, J., & Nemunaitis, J. J. (2010) · Head & Neck · doi:10.1002/hed.21364 · Cited by 65 · see citing works
China offers alternative gateway for experimental drugs
Jia, H., & Kling, J. (2006) · Nature Biotechnology · doi:10.1038/nbt0206-117 · Cited by 64 · see citing works
Antiviral Antibodies Target Adenovirus to Phagolysosomes and Amplify the Innate Immune Response
Zaiss, A. K., Vilaysane, A., Cotter, M. J., Clark, S. A., Meijndert, H. C., Colarusso, P., Yates, R. M., Pétrilli, V., Tschopp, J., & Muruve, D. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804269 · Cited by 58 · see citing works
Mechanistic Aspects of Adenovirus Serotype 2 Inactivation with Free Chlorine
Page, M. A., Shisler, J. L., & Mariñas, B. J. (2010) · Applied and Environmental Microbiology · doi:10.1128/aem.02267-09 · Cited by 58 · see citing works
Oncolytic (replication-competent) adenoviruses as anticancer agents
Tóth, K., Dhar, D., & Wold, W. S. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903559822 · Cited by 57 · see citing works
Self-citation
Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial
Tian, G., Liu, J., Zhou, J., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832a2df9 · Cited by 55 · see citing works
SR-A and SREC-I Are Kupffer and Endothelial Cell Receptors for Helper-dependent Adenoviral Vectors
Piccolo, P., Vetrini, F., Mithbaokar, P., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.287 · Cited by 53 · see citing works
Survival of Adenovirus Types 2 and 41 in Surface and Ground Waters Measured by a Plaque Assay
Rigotto, C., Hanley, K. W., Rochelle, P. A., et al. (2011) · Environmental Science & Technology · doi:10.1021/es103922r · Cited by 53 · see citing works
Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial
Atencio, I. A., Grace, M. J., Bordens, R., et al. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700870 · Cited by 50 · see citing works
Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China
Tagawa, M. (2008) · Drug Design Development and Therapy · doi:10.2147/dddt.s3535 · Cited by 49 · see citing works
Clinical Development of Oncolytic Viruses in China
Liang, M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800958760 · Cited by 49 · see citing works
Effect of Exposure to UV-C Irradiation and Monochloramine on Adenovirus Serotype 2 Early Protein Expression and DNA Replication
Sirikanchana, K., Shisler, J. L., & Mariñas, B. J. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.02049-07 · Cited by 49 · see citing works
A review of contusugene ladenovec (Advexin) p53 therapy.
Senzer, N. N., & Nemunaitis, J. J. (2009) · PubMed · Cited by 44 · see citing works
Prospects for oral replicating adenovirus-vectored vaccines
Deal, C. E., Pekosz, A. S., & Ketner, G. W. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.016 · Cited by 43 · see citing works
Increasing the Efficacy of Oncolytic Adenovirus Vectors
Tóth, K., & Wold, W. S. M. (2010) · Viruses · doi:10.3390/v2091844 · Cited by 43 · see citing works
Self-citation
An update on gene therapy in China.
Shi, J., & Zheng, D. (2009) · PubMed · Cited by 42 · see citing works
Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer
Koski, A., Raki, M., Nokisalmi, P., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.230 · Cited by 40 · see citing works
The dl1520 Virus Is Found Preferentially in Tumor Tissue after Direct Intratumoral Injection in Oral Carcinoma
Morley, S. E., MacDonald, G., Kirn, D. H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0443 · Cited by 39 · see citing works
Prevalence of human adenoviruses in raw and treated water
Heerden, J. V., Ehlers, M. M., van Zyl, W. B., et al. (2004) · Water Science & Technology · doi:10.2166/wst.2004.0013 · Cited by 37 · see citing works
Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver
Au, T., Thorne, S. H., Korn, W. M., Sze, D. Y., Kirn, D. H., & Reid, T. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700988 · Cited by 35 · see citing works
Dr. Gary J. Becker Young Investigator Award: Intraarterial Adenovirus for Metastatic Gastrointestinal Cancer: Activity, Radiographic Response, and Survival
Sze, D. Y., Freeman, S. M., Slonim, S. M., et al. (2003) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000058422.01661.1e · Cited by 34 · see citing works
Clinical Adenoviral Gene Therapy for Prostate Cancer
Schenk, E., Essand, M., & Bangma, C. H. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.206 · Cited by 30 · see citing works
Targeted genetic and viral therapy for advanced head and neck cancers
Huang, P., Chang, J.-F., Kirn, D. H., & Liu, T. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.03.008 · Cited by 27 · see citing works
Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy.
Demers, G. W., Johnson, D. E., Tsai, V., et al. (2003) · PubMed · Cited by 24 · see citing works
Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo.
Strauss, R., & Lieber, A. (2009) · PubMed · Cited by 23 · see citing works
[Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer].
Yuan, Z. Y., Zhang, L., Li, S., et al. (2003) · PubMed · Cited by 23 · see citing works
Oncolytic Virotherapy Trials—Letter
Hemminki, A., Oksanen, M., & Merisalo-Soikkeli, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1471 · Cited by 20 · see citing works
Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma
He, Q. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i18.2353 · Cited by 19 · see citing works
Ex vivo detection of adenovirus specific CD4+ T-cell responses to HLA-DR-epitopes of the Hexon protein show a contracted specificity of THELPER cells following stem cell transplantation
Serangeli, C., Bicanic, O., Scheible, M. H., et al. (2009) · Virology · doi:10.1016/j.virol.2009.10.049 · Cited by 17 · see citing works
Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents
Vaillancourt, M. T., Atencio, I. A., Quijano, E., et al. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700840 · Cited by 16 · see citing works
Oncolytic adenoviruses for the treatment of brain tumors.
Gomez‐Manzano, C., & Fueyo-Margareto, J. (2010) · PubMed · Cited by 15 · see citing works
Oncolytic Virus as an Agent for the Treatment of Malignant Ascites
Liu, H., & Chen, J. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0559 · Cited by 11 · see citing works

Flagged first, then by citations

Research works printed but not linked: 4

[1]Berk AJ Knipe DM Howley PM Adenoviridae Fields Virology 2013 Philadelphia, PA Lippincott Williams & Wilkins 1704 1731
[2]Wold WSM Ison MG Knipe DM How-ley PM Adenoviruses Fields Virology 2013 Philadelphia, PA Lippincott Williams & Wilkins 1732 1767
[71]Reid T Warren R Kirn D Intravascular adenoviral agents in cancer patients: Lessons from clinical trials Cancer Gene Ther 2002 9 979 986 12522437 PMC7091735
[111]Gordon YJ Aoki K Kinchington PR Pepose JS Holland GN Wilhelmus KR Adenovirus keratoconjunctivitis Ocular infectin and immunity 1996 St. Louis Mosby

Sorted by citations

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747 · see citing works
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404 · see citing works
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055 · see citing works
Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691 · see citing works
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579 · see citing works
Viral <scp>vector‐based</scp> gene therapies in the clinic
Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269 · see citing works
Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges
Ghosh, S., Brown, A. M., Jenkins, C., & Campbell, K. (2020) · Applied Biosafety · doi:10.1177/1535676019899502 · Cited by 218 · see citing works
Rapid development and deployment of high‐volume vaccines for pandemic response
Kis, Z., Kontoravdi, C., Dey, A. K., Shattock, R., & Shah, N. (2020) · Journal of Advanced Manufacturing and Processing · doi:10.1002/amp2.10060 · Cited by 105 · see citing works
Exosome-based delivery of super-repressor IκBα ameliorates kidney ischemia-reperfusion injury
Kim, S., Lee, S. A., Yoon, H., Kim, M. Y., Yoo, J.-K., Ahn, S.-H., Park, C. H., Park, J., Nam, B. Y., Park, J. T., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.04.039 · Cited by 100 · see citing works
Humoral immune responses to <scp>AAV</scp> gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52 · see citing works
Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy
Ren, D., Fisson, S., Dalkara, D., & Ail, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091973 · Cited by 52 · see citing works
Liver-resident CD103+ dendritic cells prime antiviral CD8+ T cells in situ
Krueger, P. D., Kim, T. S., Sung, S.-S. J., Braciale, T. J., & Hahn, Y. S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402622 · Cited by 42 · see citing works
Genetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36 · see citing works
Viral gene delivery vectors: the next generation medicines for immune-related diseases
De Haan, P., Van Diemen, F. R., & Toscano, M. G. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1757989 · Cited by 34 · see citing works
The Ocular Gene Delivery Landscape
Sahu, B., Chug, I., & Khanna, H. (2021) · Biomolecules · doi:10.3390/biom11081135 · Cited by 28 · see citing works

600. Local Sustained Delivery of Oncolytic Adenovirus with Injectable Alginate Gel for Cancer Virotherapy
(2012) · Molecular Therapy · doi:10.1016/s1525-0016(16)36404-8
Photoactivatable oncolytic adenovirus for optogenetic cancer therapy
Hagihara, Y., Sakamoto, A., Tokuda, T., Yamashita, T., Ikemoto, S., Kimura, A., Haruta, M., Sasagawa, K., Ohta, J., Takayama, K., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02782-6 · Cited by 22 · see citing works
The application of conditionally replication adenovirus-mediated suicide gene HSV-tk in the tumor gene therapy
Huang, Q. (2006) · Xiandai shengwu yixue jinzhan
Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy
Choi, J.-W., Kang, E., Kwon, O.-J., Yun, T. J., Park, H.-K., Kim, P.-H., Kim, S., Kim, J. H., & Yun, C.-O. (2013) · Gene Therapy · doi:10.1038/gt.2013.10 · Cited by 55 · see citing works
Tropism and transduction of oncolytic adenovirus vectors in prostate cancer therapy
Wu, C., Wei, F., Xu, Z., Wen, R.-M., Chen, J., Wang, J., & Mao, L. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4993 · Cited by 4 · see citing works

Authors: Wold, W., & Toth, K.
Affiliations: Saint Louis University (US)
Corresponding author: Wold, William
Venue: Current Gene Therapy
Publisher: Bentham Science Publishers Ltd.
Published: 2014-01-31
Volume: 13
Issue: 6
Pages: 421-433
ISSN: 1566-5232 (ISSN-L)
DOI: 10.2174/1566523213666131125095046
PMC: PMC4507798
OpenAlex: W1982712041
Cited by: 555
References: 112
Citations by year: 2026: 28 · 2025: 46 · 2024: 49 · 2023: 55 · 2022: 52 · 2021: 89 · 2020: 73 · 2019: 42 · 2018: 31 · 2017: 39 · 2016: 30 · 2015: 14 · 2014: 6
FWCI: 19.43
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Current Gene Therapy (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (R01AA011802)
National Cancer Institute (R01CA118022, R01 CA11802)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: adenoviral vector, gene therapy, oncolytic adenovirus, replication-defective adenovirus, replication-competent adenovirus, cancer gene therapy, viral vaccines, clinical trials
MeSH terms: Adenoviridae, Animals, Clinical Trials as Topic, DNA Replication, Genetic Vectors, Humans, Neoplasms, Vaccination, Virus Replication, Genetic Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks